AGP Executive Report

Psychedelics Push: Trump’s order to speed psychedelic drug development is already pulling investor interest, with executives saying calls picked up fast—though researchers warn real treatments are still far off. Cannabis Politics: A 41-group coalition just flooded Capitol Hill urging Congress to pass federal legalization, free cannabis prisoners, and expunge records after rescheduling momentum. Cannabis Litigation: A major “Big Tobacco”-style class action targets large cannabis brands over marketing claims, raising fresh insurance and legal risk for multistate operators. Health Research: New findings keep challenging stereotypes—cannabis extracts may affect weight and diabetes risk, while another study links cannabis-plus-tobacco “co-use” to much higher long-term psychosis risk. Public Health & Safety: Monsanto agreed to pay Rhode Island at least $25M for PCB pollution cleanup, and families are being warned about pollen exposure from hanging laundry outside.

Cannabis & mental health: A new multi-site study tracking over 1,000 young people at clinical risk finds “co-use” of cannabis and tobacco nearly triples the chance of later developing full psychotic disorders—while either alone mainly worsens short-term symptoms. Cannabis litigation watch: A major 320-page class action, Murray v. Cresco, filed May 4, targets big multistate cannabis operators’ marketing practices across 12 states, explicitly drawing “Big Tobacco” style parallels—something insurers and underwriters are already bracing for. Public health/food: A small double-blind trial (95 adults) reports daily fresh coconut water for 8 weeks improved gut inflammation symptoms in mild-to-moderate ulcerative colitis, with higher remission and lower inflammation markers than placebo. Drug enforcement: Nigeria’s NDLEA says it seized military-grade ammunition hidden in garri cassava granules and also intercepted cocaine and opioids in outbound shipments.

Cannabis + Tobacco Warning: A new multi-site study tracking over 1,000 young people at early risk for psychosis found that co-use of cannabis and tobacco nearly triples the chance of developing full psychotic disorders over time—while each alone mainly worsens short-term symptoms. ADHD Brain Mapping: A large MRI study of nearly 1,900 kids suggests ADHD can split into distinct brain profiles, helping explain why some children’s struggles look more like emotional and behavioral disruption than “just attention.” CBD Under Threat: A Medicare/Medicaid hemp reimbursement pilot could get derailed by a new federal hemp ban, which critics say would criminalize many CBD products. Vet Alerts: U.S. veterinarians report more “pot dogs” after pets ingest concentrated THC edibles, with symptoms that can be hard to spot early. Public Health Angle: Separate coverage highlights a surge in drugged-driving concerns and ongoing fentanyl unpredictability.

Cannabis ER Surge: Doctors are seeing more cases of cannabinoid hyperemesis syndrome—violent vomiting and relief only after hot showers—pushing longtime users into emergency care. Youth Brain Risk: UC San Diego adds to the warning pile with long-term findings linking childhood cannabis use to weaker cognitive development. Policy Watch: North Carolina reports infant mortality hitting a record low, but child deaths (ages 1–17) aren’t improving—while the state also flags vaping and cannabis as part of youth protection priorities. Local Access Moves: Alabama’s first medical dispensary says patients are “days away,” with product testing and tracking still the last hurdles. Other Health Signals: A new review links cannabis use disorder with higher rates of major depression, though researchers still can’t pin down cause. Science & Materials: Cactus waste could become low-cost building material, and a rare-earth-harvesting fern may help ease supply crunches.

Adolescent Brain Alarm: UC San Diego reports childhood cannabis use can restrict cognitive development, adding to growing concerns that teen pot isn’t a “safe” experiment. Cannabis vs. Health Policy: In the background, the federal rescheduling fight keeps heating up, while Medicare is set to let some patients get free CBD—an attempt to move cannabinoids into mainstream healthcare. State-by-State Access: Georgia expands medical cannabis rules (including product changes), and Alabama’s first dispensary is “days away,” though testing and tracking still slow the rollout. Pesticide Court Showdown: A Roundup/glyphosate debate resurfaces as Farm Action’s Angela Huffman argues against pesticide immunity, setting up another clash over corporate accountability. Public Safety Reality Check: A new NTSB update finds drugs—including THC—show up more often in fatal pilot testing, and a Bronx shootout left a 5-year-old grazed as a 15-year-old was arrested.

CBD for Medicare: Thousands of older adults may soon get free CBD as the Trump administration pilots mainstream coverage for the non-intoxicating cannabinoid, aiming to track whether it helps chronic pain and cuts costs. Safety Alarm: A new NTSB aviation report says nearly 1 in 3 fatally injured pilots had potentially impairing drugs onboard, with THC showing up more often—raising fresh pressure on drug-impaired driving and workplace rules. IBD Push: New York’s cannabis regulator is launching a clinical study of CBD+THC for inflammatory bowel disease, while separate trial coverage claims daily fresh coconut water improved ulcerative colitis symptoms and remission rates. Georgia Expands Access: Gov. Brian Kemp signed S.B. 220, removing the 5% THC cap, expanding qualifying conditions, and allowing more THC product types for medical patients. Psychedelics Momentum: A new poll finds growing public support for regulated psychedelic therapy with safety guardrails. Ongoing Concern: Researchers warn marijuana smoke may raise lung and head/neck cancer risk, especially with heavy use.

Georgia Medical Cannabis Expansion: Gov. Brian Kemp signed S.B. 220, replacing “low THC oil” with “medical cannabis,” removing the 5% THC cap and allowing higher-dose products (up to 12,000 mg) plus edibles, gummies, and vaporized flower; renewals get easier for “incurable/irreversible” conditions and the qualifying list expands to include lupus, autism, Stage III HIV, severe Alzheimer’s, and inflammatory bowel disease. Regulated Research Push: New York’s cannabis regulator is launching a first-of-its-kind IBD study testing daily CBD/THC doses to move beyond anecdotes. Safety Warning (Teens/Brain): Missouri experts warn adolescent cannabis use may raise mental health and psychosis risks, while other coverage highlights doctors urging against self-medicating. Enforcement & Access Tension: Victoria’s cannabis club pleads for help as the province seeks forfeiture, and Colorado regulators privately admit illegal hemp conversion into marijuana may be far bigger than they’ve said. Real-World Harm: A UK court jailed an e-bike rider for killing an 86-year-old on a zebra crossing, with cannabis and an illegal, defective bike central to the case.

Federal Cannabis Rescheduling: The U.S. moved cannabis from Schedule I to Schedule III for the first time in more than 50 years, and Montana policy expert Jamie Pearson says the real-world impact will hinge on how states implement the change. State Medical Access Boom: Georgia signed a bill expanding medical cannabis—removing the THC cap, adding vaping, and adding lupus—while Alabama’s first dispensary is “days away,” and New Jersey faces a crackdown after a doctor was suspended over medical marijuana approvals for minors. Regulation Under Pressure: Illinois is debating how to regulate surging kratom use as safety concerns grow, and Victoria’s cannabis club is asking for help as the province moves toward forfeiture. Health & Safety Alerts: A new study warns mixing cannabis with tobacco may raise psychosis risk in high-risk people, and the CDC reports nearly one-third of U.S. adults aren’t getting enough sleep. Other Drug News: Drugged driving enforcement is getting harder as younger drivers increasingly use drugs instead of alcohol.

Medical Cannabis Policy: Georgia just moved to expand medical marijuana access—adding new qualifying conditions like lupus and letting patients vape under the state program, with the THC possession framework updated as part of Gov. Brian Kemp’s signed bill. Regulatory Fight: A U.S. House committee voted to block federal marijuana rescheduling funding, even as the Trump administration pushes ahead—keeping the federal timeline messy for patients and businesses. Product Claims Under Review: A national ad watchdog backed some cannabis packaging claims for TerpLoc® but told Grove Bags to tighten messaging where performance depends on specific use conditions. Health & Safety Watch: A trial in the UK heard a driver with cannabis in her system hit a 3-year-old at a pedestrian crossing, while a separate EAT ruling found a rail worker’s discrimination case should be reconsidered after a medical-cannabis test. Global Opioid Alarm: An investigation says Indian-made tapentadol is still flooding parts of West Africa, fueling a “zombie drug” crisis.

Georgia Medical Cannabis Expansion: Gov. Brian Kemp signed SB 220, rebranding “low THC oil” as medical cannabis, adding conditions like lupus and inflammatory bowel disease, removing the old 5% THC cap, and allowing qualified patients (21+) to vape—plus higher THC limits in labeled products. Access vs. Oversight: A separate report highlights how hard UK patients still find it to get medical cannabis even after legalization wins, while a Fort Lee doctor faces a license suspension over alleged improper authorizations for minors. Public Health Pressure: New research claims coconut water may ease ulcerative colitis symptoms, and another study suggests medical cannabis could help some chronic pain patients cut opioids when cost barriers are removed. Drug-Trade Reality Check: West Africa is seeing a surge of high-strength tapentadol shipments tied to the “zombie drug” kush, and police in New Zealand seized a trailer packed with mature cannabis plants after a “strong smell” tip. Environment & Health: Greenpeace says a typical UK Sunday roast may involve 100+ pesticides, and New York lawmakers push to ban paraquat over Parkinson’s links.

Medical Cannabis Policy Moves: Georgia just expanded access to state-qualified medical cannabis—replacing “low THC oil,” removing the 5% THC cap, raising the THC possession limit to 12,000 mg, and adding new qualifying conditions like inflammatory bowel disease and lupus, plus allowing vaping for patients 21+. CBD Crackdown: France is set to ban CBD edibles starting May 15 under stricter EU “novel food” enforcement, threatening a chunk of the hemp-derived snack market. Cannabis + Mental Health Research: A new study links combined cannabis and tobacco use to higher psychosis risk in high-risk groups, adding fuel to the co-use debate. Gut Health Angle: A small double-blind trial (95 people) reports coconut water daily for 8 weeks improved ulcerative colitis symptoms and gut inflammation markers versus placebo. Food Safety Watch: A renewed push highlights glyphosate exposure concerns, pointing to WHO classification and alleged regulator inaction. Public Health Access: New York lawmakers want the state health marketplace to require senior dental plans—aimed at reducing out-of-pocket dental costs.

Cannabis + Tobacco Risk: A new Nature Mental Health multisite study finds people at clinical high risk for psychosis face higher odds when they use cannabis and tobacco together, adding to the growing concern that “co-use” may be especially destabilizing. GLP-1 Ripples: A new report on GLP-1 weight-loss drugs highlights unexpected upsides like reduced inflammation and downsides like hair thinning and excess skin. Medical Marijuana Expansion: Georgia’s governor signed SB 220 to broaden qualifying conditions, allow vaping for adults, and adjust THC limits. Older Adults Turning to Edibles: Research and interviews keep pointing to older adults using edibles for sleep, pain, and mood—often with limited medical guidance. Public Safety + Cannabis: Courts heard cases where drivers testing positive for cannabis caused serious crashes, including a child pedestrian incident. Local Health Policy: North Carolina’s Child Fatality Task Force released its 2026 report, urging stronger booster-seat enforcement and more regulation of nicotine vapes, cannabis products, and social media algorithms. Food + Chemicals: Glyphosate coverage returns with renewed calls for tighter regulation and lower exposure.

Workplace Cannabis Ruling: An employment tribunal found a rail worker may have faced disability discrimination after a medical cannabis prescription was treated as a “fail” on a mandatory drug test, raising fresh questions about how employers apply medical exemptions. Road Safety & Cannabis: In Ireland, a driver with cannabis in her system was convicted after knocking down a 3-year-old at a pedestrian crossing, with the court hearing the legal limit is zero. Health Claims Under the Microscope: A new review links cannabis use disorder with major depression, though the direction of cause is still unclear. Data Privacy Worry: A report highlights alleged schemes behind access to medical records, underscoring security gaps in how health data moves between providers. Mental Health Accountability: Commentary on the Valdo Calocane case argues police and health services faced “lack of consequences” after missed warning signs. Gut Health Trend: A small double-blind trial reports coconut water improved ulcerative colitis symptoms and inflammation markers over eight weeks.

Gut Health Boost: A small double-blind trial (95 people) reports daily fresh coconut water for 8 weeks improved mild-to-moderate ulcerative colitis symptoms, with higher remission and lower inflammation markers. Pesticide Pressure: Glyphosate is back in the spotlight—critics argue regulators aren’t doing enough as the herbicide shows up from farm fields to breakfast foods, with renewed calls for tighter rules. Cannabis & Safety: A new explainer breaks down delta-8, delta-9, THCA and why product labels can be confusing—while another story highlights rising cannabis use among older adults for sleep and pain. Addiction Reality Check: A Tennessee preacher’s son died of an overdose at 20, underscoring how addiction can resurface even after public recovery attempts. Public Health & Access: Maharashtra opened a large, low-cost municipal dialysis center in Navi Mumbai, aiming to cut the financial hit of frequent treatment. Policy Watch: Massachusetts lawmakers push bills to curb teen social media use, but experts question whether bans will actually help. Drug Detection Tech: A company touts AI voice-based intoxication detection as a faster, noninvasive alternative to current testing.

Over the last 12 hours, coverage in the Medical Bud News feed is dominated by drug- and health-policy items, with several pieces tying cannabis/psychedelics to both regulation and clinical research. A bipartisan group of lawmakers urged the FDA to “expeditiously and rapidly” review psychedelic therapies, citing urgent unmet needs in conditions including PTSD and traumatic brain injury. In parallel, a new study (published in an AMA journal) reports that a single dose of psilocybin plus psychotherapy appears “safe and efficacious” for people with cocaine use disorder, with outcomes including more cocaine abstinent days and higher complete abstinence rates. There’s also continued attention to cannabis-related risk communication: Illinois and Connecticut class-action lawsuits allege recreational marijuana sellers failed to warn consumers about health problems, and a separate piece highlights concerns about youth exposure and the “misleading use” of “CBD” to disguise synthetic drugs in Bahrain.

The same 12-hour window also includes a mix of public-health and environment-adjacent stories that intersect with “medical” themes through exposure and harm reduction. Glyphosate remains a focal point: one article frames glyphosate as a widespread food contaminant linked to major health risks and criticizes regulators for not adequately protecting the public, while another UK-focused piece describes a campaign pushing to restrict pre-harvest glyphosate use ahead of a consultation that could shape UK policy for the next 15 years. Other health-adjacent items include an Idaho prison-system report describing women punished with solitary amid overcrowding, and a spotlight on mental-health/substance-use care capacity in Iowa—arguing too few therapists are trained for co-occurring disorders.

Beyond policy and clinical research, the most “newsy” developments in the last 12 hours are criminal-justice and enforcement-related, though they’re not clearly medical breakthroughs. Police in Orlando allege rapper Kodak Black was involved in an MDMA trafficking case after a search reportedly found MDMA and cannabis in vehicles tied to him. Separately, a local report lists arrests and incidents in Cullman County, and another story describes a wrongful-death lawsuit context involving an after-prom party and a deadly crash—both illustrating ongoing enforcement and public-safety concerns around drugs and alcohol, but without direct new medical findings.

Looking across the broader 7-day range, the feed shows continuity in two threads: (1) expanding medical/therapeutic interest in psychedelics and cannabis (including rescheduling-related research access and clinician education themes), and (2) persistent controversy over cannabis marketing, youth risk, and product labeling/warnings. There’s also sustained attention to exposure risks and prevention—microplastics, glyphosate, and weed-management impacts on food systems appear repeatedly—suggesting the publication’s “medical” lens often extends to environmental and behavioral determinants of health. However, the most recent 12-hour evidence is relatively sparse on cannabis-specific clinical outcomes beyond the psilocybin/CUD study and the lawsuits, so major shifts in cannabis medicine specifically are harder to confirm from the newest items alone.

Over the last 12 hours, the most clearly “medical-adjacent” thread in the coverage is public health and substance-use policy—though much of it appears as commentary or policy discussion rather than new clinical findings. One notable policy item is Prince Edward Island considering raising the minimum age for nicotine pouches and cannabis purchases to 21, with an expert pediatrician/researcher emphasizing that age limits alone aren’t a complete solution and that enforcement and product sourcing/regulation also matter. Another substance-related item comes from a report on Israel’s medical cannabis use and rising trauma/PTSD concerns, where the coverage argues that evidence is growing that smoked medical cannabis may not help PTSD and could worsen it—alongside a proposal to phase out smoking within three years.

There’s also fresh legal/policy momentum around cannabis in the U.S., but the evidence in the most recent window is mixed between direct cannabis policy and broader drug-testing/workplace safety. In the last 12 hours, coverage includes a report that Idaho’s medical cannabis ballot effort hit a milestone with over 150,000 signatures submitted (pending clerk verification), and a separate item noting experts discussing whether age limits on nicotine pouches and cannabis are a “perfect solution” for protecting young people. In parallel, one workplace-safety piece promotes a “14-panel saliva drug test” as broader than standard panels—framing it as a response to changing drug use patterns, though it’s presented as product/implementation guidance rather than an outcome study.

Beyond cannabis, the last 12 hours include a few health-related items that are not primarily about substance policy but still intersect with medical risk. An AP report describes a hantavirus outbreak linked to a cruise ship, with evacuations and WHO case/death counts cited. Another AP item describes the U.S. firing on an Iranian oil tanker during a ceasefire period—important as a major international incident, but not medical in nature. Separately, there’s a courtroom case in Toronto where a mother found not criminally responsible for throwing her baby down a garbage chute is attributed to command auditory hallucinations and psychosis—an outcome that is clinically framed even though it’s criminal-justice coverage.

Looking back 12 to 24 hours ago, the cannabis policy/legal story becomes more corroborated and “system-level.” Multiple items point to federal and state-level scrutiny: class action lawsuits are described as being filed against major marijuana companies for alleged harms across multiple states, and the 2026 National Drug Control Strategy is described as being “very concerned about marijuana.” Together with the Idaho signature milestone and the Israel medical-cannabis/trauma discussion, the overall pattern suggests continued tightening and contestation around cannabis—both in court and in public health policy—rather than a single new breakthrough. However, because the most recent 12-hour window contains fewer direct cannabis-science updates (and more policy/legal and commentary), the continuity is clearer than any abrupt change in medical evidence.